CLAIMS

1. A compound of Formula I



(I)

wherein:

two of X^1, X^2, X^3, and X^4 are CR^5, and two are N; or three of X^1, X^2, X^3, and X^4 are CR^5, and the other is N;

Y is aryl or heteroaryl, each of which is optionally substituted by one or more substituents independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, and C_{1-4}haloalkyl;

R^1 and R^2:

(A) are both phenyl optionally substituted with one or more substituents independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, and C_{1-4}haloalkyl, and wherein the phenyl groups are optionally linked by a bond or a C_{1-2}alkylene moiety; OR

(B) together with the carbon atom to which they are attached form a 4- to 10-membered cycloalkyl or a 4- to 10-membered heterocyclyl ring, wherein the cycloalkyl or heterocyclyl ring:

a. is optionally substituted with one or more substituents independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, and C_{1-4}haloalkoxy;

b. optionally comprises one or two C=C double bonds;

c. is optionally bridged by a C_{1-3}alkylene group connecting two carbon atoms of the ring; and

d. is optionally spiro-attached to a C_{3-5}cycloalkyl groups;

R^3 is hydrogen, fluoro, or C_{1-4}alkyl;

R^4 is:

(A) a 5- to 10-membered heteroaryl optionally substituted by one or more substituents independently selected from hydroxy, halo, C_{1-4}alkyl, C_{1-}

$_4$alkoxy, C_{1-4}haloalkyl, cyano, NR^6R^7, $C(O)NR^8R^9$, CO_2R^{10}, and C_{1-3}alkylene-R^{11};

(B) 5- to 6-membered heteroaryl ring, said ring being fused to a 5- or 6-membered cycloalkyl or heterocyclyl ring, each of which is optionally substituted by one or more substituents independently selected from hydroxy, halo, oxo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, cyano NR^6R^7, $C(O)NR^8R^9$, CO_2R^{10}, and C_{1-3}alkylene-R^{11};

(C) a 5- or 6-membered cycloalkyl or a 5- or 6-membered heterocyclyl ring, said ring being fused to a phenyl or 5- to 6-membered heteroaryl ring, each of which rings is optionally substituted by one or more substituents independently selected from hydroxy, halo, oxo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, cyano, NR^6R^7, $C(O)NR^8R^9$, CO_2R^{10}, and C_{1-3}alkylene-R^{11}; OR

(D) a partially unsaturated heterocyclic ring, optionally fused to a 5- to 6-membered heteroaryl ring and optionally substituted with one or more substituents independently selected from hydroxy, halo, oxo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, cyano, NR^6R^7, $C(O)NR^8R^9$, CO_2R^{10}, and C_{1-3}alkylene-R^{11};

R^5 is hydrogen, fluoro, chloro, methyl, methoxy, or trifluoromethyl;

R^{11} is hydroxy, halo, C_{1-4}alkoxy, cyano, $NR^{12}R^{13}$, $C(O)R^{14}$, aryl or heteroaryl;

R^{14} is hydroxy, C_{1-4}alkyl, C_{1-4}alkoxy or $NR^{15}R^{16}$;

R^6, R^7, R^8, R^9, R^{10}, R^{12}, and R^{13} are independently selected from hydrogen and C_{1-4}alkyl;

R^{15} and R^{16} are independently selected from hydrogen and C_{1-4}alkyl; or

R^{15} and R^{16}, taken together with the nitrogen atom to which they are attached, form a 3- to 7-membered heterocyclyl ring, the ring optionally containing a further heteroatom chosen from O, S, and N and being optionally substituted with C_{1-4}alkyl;

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein X^1 is N and X^2, X^3, and X^4 are CH.

3. The compound according to claim 1 or claim 2, wherein Y is:

i. heteroaryl optionally substituted by one or more substituents independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, and C_{1-4}haloalkyl;

ii. a 5- or 6-membered heteroaryl ring optionally substituted by one or more substituents independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, and C_{1-4}haloalkyl;

iii. a heteroaryl ring optionally substituted by one or more substituents independently selected from halo, C_{1-3}alkyl, C_{1-2}alkoxy, and C_{1-2}haloalkyl;

iv. a 5- to 6-membered heteroaryl optionally substituted by one or more substituents independently selected from halo and methyl;

v. a 5- to 6-membered heteroaryl ring substituted in a position *ortho* to the NHC(O)-moiety by methyl or ethyl; or

vi. a group selected from:



wherein ~~~ is the point of attachment to the rest of the compound of Formula I and Y is optionally substituted by one or more substituents independently selected from halo, C_{1-3}alkyl, C_{1-2}alkoxy, and C_{1-2}haloalkyl.

4. The compound according to any one of claims 1 to 3, wherein R^1 and R^2 are both phenyl optionally substituted with one or more substituents independently selected from fluoro and methyl.

5. The compound according to any one of claims 1 to 3, wherein R^1 and R^2 together with the carbon atom to which they are attached form:

i. a 5- to 8-membered cycloalkyl ring, wherein the cycloalkyl ring:
   a. is optionally substituted with one or more substituents independently selected from halo, C_{1-2}alkyl, C_{1-2}alkoxy, and C_{1-2}haloalkyl;
   b. optionally comprises one or two C=C double bonds;
   c. is optionally bridged by a C_{1-3}alkylene group connecting two carbon atoms of the ring; and
   d. is optionally spiro-attached to a C_{3-5}cycloalkyl group;

ii. a group selected from:



wherein * is the carbon atom to which R^1 and R^2 are attached, each occurrence of R^{17} is independently selected from halo, C_{1-2}alkyl, C_{1-2}alkoxy, and C_{1-2}haloalkyl, and m is 0,1, 2 or 3; or

iii. the following group:



,

wherein * is the carbon atom to which R^1 and R^2 are attached, and each R^{17} is independently selected from hydrogen, fluoro, methyl, and trifluoromethyl.

6. The compound according to any one of claims 1 to 5, wherein R^3 is hydrogen.

7. The compound according to any one of claims 1 to 6, wherein R^4 is:

i. a 5- to 10-membered heteroaryl optionally substituted by one or more substituents independently selected from hydroxy, halo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-2}fluoroalkyl, cyano, NR^6R^7, $C(O)NR^8R^9$, and C_{1-3}alkylene-R^{11};

ii. a 5- to 6-membered monocyclic heteroaryl ring, or a 9- to 10-membered bicyclic heteroaryl ring, optionally substituted by one or more substituents independently selected from fluoro, chloro, methyl, methoxy, trifluoromethoxy, cyano, NR^6R^7, and CH_2-R^{11}; or

iii. a partially unsaturated heterocyclic ring, optionally fused to a 5- to 6-membered heteroaryl ring and optionally substituted with one or more substituents independently selected from hydroxy, halo, oxo, C_{1-2}alkyl, C_{1-2}alkoxy, C_{1-2}haloalkyl, and cyano.

8. The compound according to any one of claims 1 to 6, wherein R^4 is selected from one of the following groups:



wherein:

~~~ is the point of attachment to the rest of the compound of Formula I;

R^{18} is independently selected from hydroxy, halo, $C_{1\text{-}4}$alkyl, $C_{1\text{-}4}$alkoxy, $C_{1\text{-}4}$haloalkyl, cyano, NR^6R^7, and $C_{1\text{-}3}$alkylene-R^{11};

R^{19} is independently selected from hydrogen, $C_{1\text{-}4}$alkyl, and $C_{1\text{-}3}$alkylene-R^{11}; and

p is 0, 1 or 2;

wherein when R^4 is a bicyclic group and p is 1 or 2, then each R^{18} substituent may be present on either ring of the bicyclic group.
~~~

9. The compound according to claim 8, wherein R^{18} is independently selected from hydroxy, fluoro, chloro, methyl, methoxy, CF_3, NR^6R^7, and C_{1-3}alkylene-R^{11}; and R^{19} is independently selected from hydrogen, and methyl.

10. The compound according to claim 1, wherein the compound has one of the structural Formulae IA, IB, IC or ID shown below:



(IA)



(IB)



(IC)



(ID)

,

wherein X^1 to X^4, Y and R^4 are as defined in any one of claims 1 to 9; each R^{17} is independently selected from hydrogen, halo, C_{1-2}alkyl, C_{1-2}alkoxy, and C_{1-2}haloalkyl; and n is 1, 2, 3 or 4.

11. The compound according to claim 1, wherein the compound has one of the structural Formulae IE, IF, IG, IH, IJ, IK, IL or IM shown below:



(IE)



(IF)



(IG)



(IH)



(IJ)



(IK)



(IL)



(IM),

wherein Y, R^1, R^2, R^3, R^4 and R^5 are as defined in any one of claims 1 to 9; each R^{17} is independently selected from halo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, and C_{1-4}haloalkoxy; R^{20} and R^{21} are independently selected from hydrogen, halo, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}haloalkyl, and C_{1-4}haloalkoxy; and m is 0 to 4.

12. The compound according to claim 11, wherein R^{20} and R^{21} are independently selected from hydrogen, fluoro, methyl, trifluoromethyl, and methoxy; and m is 0.

13. The compound according to claim 11 or claim 12, wherein each R^5 is hydrogen.

14. The compound according to claim 1, wherein the compound is selected from one of the following compounds:
(S)-N-(1-((1',2'-dimethyl-6'-oxo-1',6'-dihydro-[3,3'-bipyridin]-6-yl)amino)-1-oxo-3,3-diphenylpropan-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-((3',5'-dimethyl-[3,4'-bipyridin]-6-yl)amino)-1-oxo-3,3-diphenylpropan-2-yl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((1',2'-dimethyl-6'-oxo-1',6'-dihydro-[3,3'-bipyridin]-6-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((3',5'-dimethyl-[3,4'-bipyridin]-6-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((1',2'-dimethyl-6'-oxo-1',6'-dihydro-[3,3'-bipyridin]-6-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((3',5'-dimethyl-[3,4'-bipyridin]-6-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-(1-Cyclooctyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(*S*)-*N*-(1-Cyclohexyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-isopropyl-1*H*-pyrazole-5-carboxamide;
N-((*S*)-2-((5-(3,5-Dimethylisoxazol-4-yl)pyridin-2-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1*H*-pyrazole-5-carboxamide;
N-((*S*)-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-1-isopropyl-1*H*-pyrazole-5-carboxamide;
N-((*S*)-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((*S*)-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
N-(1-Cyclooctyl-2-((5-(1,4-dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;

(*S*)-*N*-(1-Cyclohexyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1*H*-1,2,3-triazole-5-carboxamide;
(*S*)-*N*-(1-Cyclohexyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-ethyl-1*H*-pyrazole-5-carboxamide;
N-((*S*)-2-((5-(3,5-Dimethylisoxazol-4-yl)pyridin-2-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide;
(*S*)-*N*-(1-Cyclohexyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-ethyl-1*H*-pyrazole-5-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-isopropyl-1*H*-pyrazole-5-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((*S*)-2-((5-(1,4-Dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1*H*-pyrazole-5-carboxamide;
N-((*S*)-2-((5-(1,4-Dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide;
(*S*)-*N*-(1-Cyclohexyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;
(*S*)-*N*-(1-Cyclohexyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1,2,3,4-tetrahydropyrrolo[1,2-*a*]pyrazine-6-carboxamide;
N-((*S*)-2-((5-(1,4-Dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(1,4-dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;

(*S*)-*N*-(1-Cycloheptyl-2-((5-(1,4-dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1*H*-1,2,3-triazole-5-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(1,4-dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-4-methyl-1,2,5-oxadiazole-3-carboxamide;
N-((*S*)-2-((2-(3,5-dimethylisoxazol-4-yl)pyrimidin-5-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(1,4-dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
(*S*)-*N*-(1-Cycloheptyl-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-(methoxymethyl)isoxazole-4-carboxamide;
N-((*S*)-2-((6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;
6-((*S*)-2-(1-Ethyl-1H-pyrazole-5-carboxamido)-2-((1*r*,4*S*)-4-methylcyclohexyl)acetamido)-3',5'-dimethyl-[3,4'-bipyridine] 1'-oxide;
3-ethyl-N-((S)-1-((1r,4S)-4-methylcyclohexyl)-2-((5-(5-methylpyrimidin-4-yl)pyridin-2-yl)amino)-2-oxoethyl)isoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-ethyl-1H-1,2,3-triazole-5-carboxamide;
N-((S)-2-((5-(3-(methoxymethyl)-5-methylisoxazol-4-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(3,5-dimethyl-4H-1,2,4-triazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-(4,4-difluorocyclohexyl)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((6-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
1-methyl-N-((S)-2-((4-methyl-5-(1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide;
N-((S)-2-((2-(1,4-dimethyl-1H-pyrazol-5-yl)pyrimidin-5-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(5-(methoxymethyl)-3-methylisoxazol-4-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;

N-((S)-2-((3'-methoxy-2'-methyl-[3,4'-bipyridin]-6-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((2',3'-dimethyl-[3,4'-bipyridin]-6-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((2',5'-dimethyl-[3,4'-bipyridin]-6-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((6-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((6-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((2-(1,4-dimethyl-1H-pyrazol-5-yl)pyrimidin-5-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(1-ethyl-4-methyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)pyrazin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(1-cyclopropyl-4-methyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)-3-fluoropyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)-3-fluoropyridin-2-yl)amino)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(3,5-dimethylisoxazol-4-yl)-3-fluoropyridin-2-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyrimidin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(4-hydroxy-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-1,2,3-triazole-5-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-1,2,3-triazole-5-carboxamide;

(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(4-cyclopropyl-1-methyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(2-((5-(4-chloro-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-cycloheptyl-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(2-((5-(4-chloro-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-cycloheptyl-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(S)-N-(2-((5-(4-chloro-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-cycloheptyl-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cyclohexyl-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cyclohexyl-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((6-(1,4-dimethyl-1H-pyrazol-5-yl)-5-fluoropyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((6-(1,4-dimethyl-1H-pyrazol-5-yl)-5-fluoropyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(S)-N-(1-cyclohexyl-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-methylisoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(4-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cyclopentyl-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-(1-(bicyclo[2.2.1]heptan-2-yl)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-(2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxo-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)ethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-(2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxo-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)ethyl)-1-ethyl-1H-pyrazole-5-carboxamide;

N-(2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxo-1-((1r,4r)-4-(trifluoromethyl)cyclohexyl)ethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((6-(1,4-dimethyl-1H-pyrazol-5-yl)-5-fluoropyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(1-(2-(dimethylamino)-2-oxoethyl)-4-methyl-1H-1,2,3-triazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-isopropylisoxazole-4-carboxamide;
3-(tert-butyl)-N-((S)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)isoxazole-4-carboxamide;
N-((S)-2-((5-(4-cyano-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-(trifluoromethyl)isoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-oxo-2-((5-(1,3,4-trimethyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)ethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(3,5-dimethylisothiazol-4-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(3,5-dimethylisothiazol-4-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-1,2,3-triazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(4-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(4-chloro-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((5-(4-chloro-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-1,2,3-triazole-5-carboxamide;
N-((S)-2-((5-(4-chloro-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-((5-(4-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((6-(1,4-dimethyl-1H-pyrazol-5-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-isopropyl-1H-pyrazole-5-carboxamide;

1-ethyl-N-((S)-2-((5-(4-(hydroxymethyl)-1-methyl-1H-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1H-pyrazole-5-carboxamide;
N-((S)-2-((6-(3,5-dimethylisoxazol-4-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-isopropyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cyclohexyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-1-methyl-1H-1,2,3-triazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
N-((S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-1-ethyl-1H-pyrazole-5-carboxamide;
N-((S)-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-1-((1r,4S)-4-methylcyclohexyl)-2-oxoethyl)-3-ethylisoxazole-4-carboxamide;
(S)-N-(1-cycloheptyl-2-oxo-2-((1',2',4'-trimethyl-6'-oxo-1',6'-dihydro-[3,3'-bipyridin]-6-yl)amino)ethyl)-1-methyl-1H-pyrazole-5-carboxamide;
1-methyl-N-((S)-1-((1r,4S)-4-methylcyclohexyl)-2-oxo-2-((1',2',4'-trimethyl-6'-oxo-1',6'-dihydro-[3,3'-bipyridin]-6-yl)amino)ethyl)-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-oxo-2-((5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)ethyl)-1-methyl-1H-pyrazole-5-carboxamide;
1-methyl-N-((S)-1-((1r,4S)-4-methylcyclohexyl)-2-oxo-2-((5-(1,3,5-trimethyl-1H-pyrazol-4-yl)pyridin-2-yl)amino)ethyl)-1H-pyrazole-5-carboxamide;
(S)-N-(1-cycloheptyl-2-((6-(3,5-dimethyl-1H-pyrazol-4-yl)pyridin-3-yl)amino)-2-oxoethyl)-1-methyl-1H-pyrazole-5-carboxamide;
1-methyl-*N*-((*S*)-2-((5-(1-methyl-4-(trifluoromethyl)-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-1-((1*r*,4*S*)-4-methylcyclohexyl)-2-oxoethyl)-1*H*-pyrazole-5-carboxamide; and
N-(2-((5-(1,4-dimethyl-1*H*-pyrazol-5-yl)pyridin-2-yl)amino)-1-(dispiro[2.1.2^{5}.2^{3}]nonan-4-yl)-2-oxoethyl)-1-methyl-1*H*-pyrazole-5-carboxamide;
or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

16. A compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 15, for use in therapy.

17. A compound according to any one of claims 1 to 14, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 15, for use in the treatment of acute lung injury, Alzheimer's Disease, ankylosing spondylitis, axial spondyloarthritis and other spondyloarthropathies, arthritis, asthma (including severe asthma), atopic dermatitis, autoimmune diabetes other autoimmune disorders, autoimmune thyroiditis, bone resorption, cancer (both solid tumours such as melanomas, sarcomas, squamous cell carcinomas, transitional call cancers, ovarian cancers and hematologic malignancies and in particular acute myelogenous leukaemia, chronic lymphocytic leukemia, gastric cancer, and colon cancer), Castleman's disease, contact dermatitis, Crohn's Disease, chronic myelogenous leukemia, chronic obstructive pulmonary disease (COPD), coeliac disease, cystic fibrosis, dermatomyositis, discoid lupus erythematosus, eczema, enthesitis-related arthritis, endotoxic shock associated with infection, exophthalmos, fibrosing disorders including pulmonary fibrosis, gall bladder disease, giant cell arteritis, graft-versus-host disease, heart disease including ischaemic diseases such as myocardial infarction as well as atherosclerosis, hepatoblastomas, hypochlorhydia, immune mediated inflammatory disorders of the central and peripheral nervous system such as multiple sclerosis and Guillain-Barr syndrome, infections (viral, bacterial, fungal, and parasitic), inflammatory bowel disease, intravascular coagulation, irritable bowel syndrome, liver fibrosis, lyme arthritis, meningoencephalitis, myocarditis, meningoencephalitis, osteoporosis, pancreatitis, Parkinson's disease, pelvic inflammatory disease, pain (particularly pain associated with inflammation), periodontitis, peritonitis, Peyronie's Disease, Pilonidal disease, psoriasis, psoriatic arthritis (PsA), renal fibrosis, rheumatoid arthritis, scleroderma or systemic sclerosis, stroke, surgical adhesions, systemic lupus erythematosus (SLE), systemic onset juvenile idiopathic arthritis (JIA), trauma (surgery), transplant rejection, Type I diabetes, ulcerative colitis, uveitis or vasculitis.